Drug intelligence / Profile preview

JS1-1

Development stage: Phase 3
Lead developer: Tasly Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JS1-1 is a novel dual-action mechanism antidepressant developed by Tasly Pharmaceutical Group Co., Ltd. It is currently in Phase 2 clinical trials for the treatment of moderate to severe depression. Preclinical and clinical studies indicate that JS1-1 and its metabolites inhibit the reuptake of dopamine, serotonin, and norepinephrine. Additionally, it exhibits agonist effects on the BDNF-TrkB/mTOR signaling pathway. This mechanism is hypothesized to lead to a rapid antidepressant effect and significant improvement in anhedonia in patients with depression. The drug is administered orally as pills.

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)mTOR (Mammalian target of rapamycin kinase)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on JS1-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS1-1.

Explore the full profile